Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWhat the evidence says about switching, and why the combination is a different question entirely
You're mid-treatment and wondering if the other medicine would have worked better
This is the scenario our prescribers hear regularly. Someone has been on semaglutide (Wegovy) for several months, weight loss has plateaued or side effects have become tiresome, and tirzepatide (Mounjaro) keeps appearing in articles as the stronger option. Or the reverse: someone has started tirzepatide and wants to know whether semaglutide is still in the picture at all.
First, the thing worth clearing up gently: a common misconception is that taking both medicines together would produce additive results, as if two slimming pens are better than one. That is not how it works. Semaglutide is a GLP-1 receptor agonist; tirzepatide activates both GLP-1 and GIP receptors. They share the GLP-1 pathway, so combining them does not simply stack two independent mechanisms, it means two medicines competing at the same receptor site, with no safety data to guide dosing and a meaningful risk of compounding side effects such as nausea, vomiting and low blood sugar in people with type 2 diabetes. If you want to understand the full clinical picture around mixing Wegovy and Mounjaro, including why concurrent use is not supported, that page covers the reasoning in detail. No licensed guidance supports concurrent use.
Switching is a different matter. A prescriber can transition a patient from one to the other based on tolerability, response and clinical history. The practical question is timing and dose: both medicines have half-lives measured in days, and the crossover point needs clinical judgement. You can read more about how that decision is approached on our tirzepatide after semaglutide page.
How semaglutide and tirzepatide compare on the measures that matter
When patients ask about mixing, they are often really asking: which one produces better results? The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, is the most direct evidence available, an open-label head-to-head involving 751 adults with obesity and no diabetes over 72 weeks. Tirzepatide produced greater average weight reduction than semaglutide 2.4mg. NICE's appraisal of tirzepatide (TA1026) also notes that indirect comparisons favour tirzepatide, while acknowledging the evidence base continues to develop.
That said, semaglutide now has a 7.2mg maintenance option following MHRA approval of the dedicated single-dose pen in April 2026, with trial data reporting around 20.7% average weight loss at that dose, narrowing the gap with tirzepatide's highest dose considerably. Cost, tolerability and individual health history all shape which medicine fits a particular person. Neither is universally the right answer.
The table below summarises the key factual differences between the two licensed weight-loss medicines in the UK.
| Feature | Semaglutide (Wegovy injection) | Tirzepatide (Mounjaro) |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist |
| Highest licensed maintenance dose (UK) | 7.2mg weekly (pen approved April 2026) | 15mg weekly |
| Average weight loss in trials | ~15% at 2.4mg (STEP 1, 68 weeks); ~20.7% at 7.2mg | ~20–21% at 15mg (SURMOUNT-1, 72 weeks) [Source: NEJM] |
| Head-to-head evidence | SURMOUNT-5 (NEJM 2025): tirzepatide produced greater average loss vs semaglutide 2.4mg over 72 weeks | |
| UK licence for weight management | Yes (BMI ≥30, or ≥27 with a weight-related condition) | Yes (same thresholds) |
| Can be combined together? | No, not studied, not recommended; concurrent use is not clinically supported | |
For a fuller side-by-side breakdown, our Wegovy versus Mounjaro page covers the clinical detail in depth. Cost differences between the two are explored on the tirzepatide vs semaglutide cost page.
What a prescriber actually considers when you want to switch
If you are already on one medicine and want to move to the other, a prescriber will look at several things before agreeing to the change: how long you have been on your current treatment, what dose you have reached, whether you have shown meaningful response, and whether there is a clinical reason the current medicine is not working. Transfer patients at nume provide evidence of their current treatment; dose increases also require documented weight evidence per our clinical policy.
The NHS tirzepatide information page and the equivalent NHS semaglutide page both set out the standard information for each medicine individually; neither endorses switching without clinical oversight. Timing matters practically too, both medicines linger in the body for a period after the last dose, and a prescriber will factor that into the crossover plan to reduce the chance of overlapping effects.
If the comparison question is really about which of the two to start on (not about switching at all) our semaglutide or tirzepatide page works through the decision factors. And if you want to understand whether the two could ever be taken together in any form, the specific clinical answer is on our can you mix tirzepatide and semaglutide page.
Which treatment is right for you is a clinical decision, made with our prescribers after a full assessment. Start your free consultation and a GPhC-registered Independent Prescriber will review your details the same day.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.